Clinical Trial Update: Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating tolerability and efficacy of Anacetrapib in patients with coronary heart disease or CHD risk-equivalent disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chd Risk-equivalent Disease
• Coronary Heart Disease

Drugs mentioned

• Anacetrapib (anacetrapib)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Coronary Heart Disease (CHD), CHD Risk-Equivalent Disease | Phase 3 | Status: COMPLETED